Environmental and genetic factors associated with morphine response in the postoperative period

Pharmacology Department, Saint Antoine University of Medicine, University Pierre et Marie Curie, Paris, France.
Clinical Pharmacology &#38 Therapeutics (Impact Factor: 7.9). 05/2006; 79(4):316-24. DOI: 10.1016/j.clpt.2006.01.007
Source: PubMed


The aim of this study was to investigate the respective influence of genetic and nongenetic factors on morphine dose requirements and adverse effects after colorectal surgery.
Seventy-four patients who planned to undergo colorectal surgery were included in this pilot study. The cumulative 24-hour postoperative dose of morphine and postoperative nausea or vomiting requiring the antiemetic ondansetron were the 2 clinical end points. The association of patient characteristics, A118G mu-opioid receptor (OPRM1) single-nucleotide polymorphism (SNP); T802C uridine diphosphate-glucuronosyltransferase 2B7 (UGT2B7) SNP; and 2 adenosine triphosphate-binding cassette, subfamily B, member 1 (ABCB1) (multidrug resistance 1 [MDR1]) exonic SNPs (G2677T/A and C3435T) with study end points was investigated.
Age, creatinine clearance, and the regular use of psychotropic agents were found to be significantly associated with postoperative morphine dose requirements by univariate analysis. Multivariate analysis identified that age (P = .01) and the use of psychotropic agents before surgery (P = .03) were positively associated with a higher rate of morphine consumption. A higher weight (P = .05) and the ABCB1 homozygous GG-CC diplotype (P = .03) were significantly associated with fewer morphine side effects by univariate analysis. The homozygous ABCB1 diplotype (GG-CC) conferred an odds ratio of 0.12 (95% confidence interval, 0.01-0.98) with regard to the use of ondansetron for postoperative nausea or vomiting. Multivariate analysis identified that the ABCB1 GG-CC diplotype was the only borderline-significant (P = .07) predictive factor of morphine side effects.
Age and prior use of psychotropic agents are associated with postoperative morphine dose requirements. Whether ABCB1 polymorphisms might predict morphine side effects remains to be determined.

Download full-text


Available from: Marc Beaussier, Apr 01, 2015
  • Source
    • "Genomic DNA was extracted from circulating blood leukocytes by using Gentra Puregene Blood Kits according to the manufacturer's protocol (Qiagen) and was stored at À 20 1C. The BDNF Val66Met polymorphism (rs 6265) was genotyped using TaqMan allelic discrimination (Coulbault et al., 2006), with the ABI Prism "
    [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: Whether the Brain Derived Neurotrophic Factor (BDNF) Val66Met polymorphism can predict antidepressant drug efficacy in depressed patients remains unclear, suggesting that it may depend on antidepressant classes. We assessed the impact of Val66Met polymorphism on antidepressant response and remission depending on antidepressant classes. METHODS: In a 6-month prospective, real-world setting, treatment study, 345 Caucasian depressed patients requiring a new or different drug treatment with a selective serotonin reuptake inhibitor (SSRI), a serotonin and noradrenalin reuptake inhibitor (SNRI) or a tricyclic antidepressant (TCA), were genotyped and assessed for response and remission. RESULTS: 231 (67%) patients were homozygous for the Val66 allele (Val/Val) and 114 (33%) were carriers of Met allele (Met). 152 (44.1%) patients were treated with SSRI, the others with SNRI/TCA. Both response and remission were explained by interactions between the Val66Met polymorphism and antidepressant drug classes (multivariate models adjusted for propensity-scores: p=0.02 and p=0.03 respectively). With SSRI, Val/Val patients had a higher response rate 3 months post-treatment than Met patients (68.1% versus 44%; adjusted-OR: 3.04, IC95% [1.05; 9.37], p=0.04). With SNRI/TCA, Val/Val patients had a lower remission rate 6 months post-treatment than Met patients (33.3% versus 60.9%, adjusted-OR: 0.27, IC95% [0.09; 0.76], p=0.02). LIMITATIONS: Limited sample size. CONCLUSIONS: This study argues for a personalized prescription of antidepressants in Caucasian patients with major depressive disorder, based on the BDNF Val66Met polymorphism: SSRI should be preferred for Val/Val patients and SNRI/TCA for Met patients. Further studies are required to confirm these data.
    Full-text · Article · Apr 2015 · Journal of Affective Disorders
    • "In conclusion, the authors concluded ABCB1 genotypes may be a clinical predictor of responsiveness for ondansetron. Coulbault et al. (2006) performed an investigation of several genomic factors, including ABCB1 polymorphism, involved in PONv. Seventy-four patients who planned to undergo colorectal surgery were included in this pilot study. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Postoperative nausea and vomiting (PONV) continues to be a most common complication of surgery and anesthesia. It has been suggested that the inherited factors may play a significant role in the background sensitivity to both PONV and also chemotherapy-induced nausea and vomiting (CINV), including resistance to antiemetic prophylaxis and/or therapy. This notion could be best exemplified by occurrence of PONV in several generations of families and concordance of PONV in monozygotic twins. The most frequently addressed issue in the research on genomic background of PONV/CINV relates to the inherited resistance to the antiemetic treatment (pharmacogenomics), and in lesser degree to their genomic background. The most common group of antiemetics consists of 5HT3 receptor antagonists, and this group was an initial target of pharmacogenomic research. Most research approaches have been based on the investigation of polymorphic variations in the target for the antiemetic 5HT3 receptor antagonists, i.e., serotonin receptor subunits A and B (HTR3A and HTR3B). The other area of pharmacogenomic investigations includes metabolic pathways of 5HT3 antagonists, in particular polymorphic variants of the CYP450 2D6 isoform (CYP2D6) because most of them are metabolized in various degrees by the CYP2D6 system. The results of targeted genomic association studies indicate that other genes are also associated with PONV and CINV, including OPRM1, and ABCB1. In addition, genes such as DRD2 and CHRM3 genes have recently been associated with PONV. The new genome-wide association studies seem also to indicate that the background genomic sensitivity to PONV and CINV might be multifactorial and include several genomic pathways.
    No preview · Article · May 2014 · Experimental Brain Research
  • Source
    • "However, the analgesic efficacy of opioids is well known to vary widely among individuals, making it difficult to predict optimal pain management for each patient (Ikeda et al. 2005). Individual differences may be related to a variety of genetic and nongenetic factors, including gender, age, ethnic origin, hepatic or renal function, and mental status (Coulbault et al. 2006). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Opioid analgesics are widely used for the treatment of moderate to severe pain. However, the analgesic efficacy of opioids is well known to vary widely among individuals, making it difficult to predict optimal pain management for each patient. The current clinical study was designed to investigate the association of the A118G single nucleotide polymorphism of the μ-opioid receptor gene with the individual variation in pain sensitivity and fentanyl consumption with patient-controlled analgesia (PCA) in 60 adult female Egyptian patients after total abdominal hysterectomy. All patients received general anesthesia according to the same protocol. During the first 24 h after surgery, pain was assessed using a visual analogue scale. In addition, total amount of fentanyl consumption, sedation score, and any other side effects of opioids were recorded; the A118G single nucleotide polymorphism of the μ-opioid receptor gene was detected by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Our main finding was that in Egyptian gynecological patients, subjects homozygous for the 118G allele needed more fentanyl (488.5 ± 23.91 μg) for 24-h postoperative analgesia than 118A homozygotes (359.82 ± 19.63 μg) and heterozygotes (400± 8.99 μg) (P = 0.001). There was no association of G or A allele and opioid side effects. This study may provide support for the potential use of genetic data in predicting patient’s individual fentanyl doses for adequate postoperative pain control.
    Full-text · Article · Jan 2014 · Comparative Clinical Pathology
Show more